All Eyes On Sanofi’s MS Efforts As Aubagio Plummets Upon Generic Entries
Dupixent Still On The Rise
The French firm’s ex-blockbuster multiple sclerosis drug, Aubagio, saw sales more than halve as generics made their mark, prompting the firm to tout recent developments for two pipeline contenders for the disease.
